Inspire Medical Systems, Inc. (NYSE:INSP) Holdings Increased by Bamco Inc. NY

Bamco Inc. NY raised its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 347,800 shares of the company's stock after acquiring an additional 8,500 shares during the quarter. Bamco Inc. NY owned 1.16% of Inspire Medical Systems worth $64,475,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in INSP. First Horizon Advisors Inc. boosted its position in Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 124 shares in the last quarter. Huntington National Bank boosted its position in shares of Inspire Medical Systems by 228.3% in the 4th quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after buying an additional 121 shares in the last quarter. Harbour Investments Inc. grew its stake in Inspire Medical Systems by 101.0% in the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after acquiring an additional 99 shares during the last quarter. AlphaQuest LLC increased its holdings in Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock valued at $55,000 after acquiring an additional 291 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its position in Inspire Medical Systems by 61.9% during the fourth quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock worth $61,000 after acquiring an additional 125 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of Inspire Medical Systems stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the completion of the transaction, the director now owns 24,046 shares of the company's stock, valued at $3,847,360. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CTO John Rondoni sold 583 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the transaction, the chief technology officer now directly owns 10,424 shares of the company's stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,527 shares of company stock valued at $4,851,660 over the last ninety days. Corporate insiders own 4.10% of the company's stock.

Inspire Medical Systems Price Performance

NYSE INSP traded down $5.01 during trading hours on Wednesday, hitting $156.87. The company had a trading volume of 735,186 shares, compared to its average volume of 587,782. The firm's 50 day moving average is $159.46 and its 200 day moving average is $179.13. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $225.00. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of 90.68, a P/E/G ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The business had revenue of $201.32 million during the quarter, compared to the consensus estimate of $194.89 million. During the same period in the prior year, the firm earned ($0.34) earnings per share. The business's quarterly revenue was up 22.7% compared to the same quarter last year. On average, equities analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on INSP shares. Robert W. Baird raised their price objective on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their price target on Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research report on Tuesday. Piper Sandler reduced their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. KeyCorp dropped their price objective on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Finally, Morgan Stanley lowered their price target on shares of Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $211.91.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.